TABLE 2

Clinical characteristics of type 2 diabetic patients with and without microalbuminuria after rosiglitazone or an alternative treatment

Without microalbuminuria
With microalbuminuria
NateglinideRosiglitazonePlacebo + previous oral antidiabetic drugRosiglitazone + previous oral antidiabetic drug
A1C (%)6.3 ± 0.36.2 ± 0.36.8 ± 0.26.6 ± 0.2
Fasting plasma glucose (mmol/l)6.9 ± 0.66.2 ± 0.47.9 ± 0.77.0 ± 0.7
Insulin sensitivity index (Mc) (mg · kg−1 · min−1)2.4 ± 0.43.7 ± 0.3*2.0 ± 0.42.9 ± 0.3*
Systolic blood pressure (mmHg)127.9 ± 4.0123.0 ± 2.7140.4 ± 3.7137.4 ± 3.3
Diastolic blood pressure (mmHg)77.8 ± 3.476.1 ± 4.084.6 ± 3.479.7 ± 2.4
MAP (mmHg)94.8 ± 3.292.6 ± 3.3103.0 ± 3.499.8 ± 3.1
Urinary albumin excretion (mg/24 h)5.6 ± 1.46.6 ± 1.9116.5 ± 31.140.4 ± 12.3*
Urinary protein excretion (mg/24 h)106.3 ± 21.097.5 ± 20.1316.57 ± 56.4106.5 ± 24.0*
Urinary sodium excretion (mmol/24 h)203.8 ± 19.9204.7 ± 19.0200.6 ± 19.1202.4 ± 17.8
Urinary urea excretion (mmol/24 h)441.9 ± 46.9435.1 ± 25.6438.5 ± 27.8432.3 ± 29.1
Plasma renin (pg/ml)20.8 ± 7.323.4 ± 6.345.6 ± 15.447.0 ± 15.1
C-reactive protein (mg/l)2.4 ± 1.11.5 ± 0.82.4 ± 0.31.8 ± 0.9
Creatinin (μmol/l)82.4 ± 5.584.7 ± 6.785.3 ± 5.085.7 ± 4.9
  • Data are means ± SE.

  • *

    * P < 0.01 vs. nateglinide or placebo.